Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies.

摘要: Abstract Epidemiological evidence supports comorbidity of generalized anxiety disorder (GAD) and major depressive (MDD) or dysthymia, its association with significant disability. As pregabalin, a new α2-δ anxiolytic treatment for GAD, unlike most other licensed treatments GAD has not undergone investigation in patients MDD, we examined efficacy symptoms associated through post-hoc analysis the existing clinical trial database. The results provide consistent that pregabalin reduced depression. This was seen 150 mg/day, 300–450 mg/day 600 mg/day dosing groups. Even subjects more prominent symptoms, remained effective both sub-syndromal depression demonstrating beneficial response. In conclusion, an alternative option novel mechanism action, also demonstrated treating typically encountered patients.